Bayesian sample size calculations in phase II clinical trials using a mixture of informative priors

Statistics in Medicine

Volumn 25, Issue 15, 2006, Pages 2554-2566

  Gajewski, Byron J ^a,b   Mayo, Matthew S ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Beta; Binomial; Mixture

Indexed keywords

ALGORITHM; ARTICLE; BAYES THEOREM; BIOSTATISTICS; CALCULATION; CLINICAL RESEARCH; CONCEPTUAL FRAMEWORK; DRUG EFFICACY; METHODOLOGY; OBSERVER VARIATION; OUTCOME ASSESSMENT; PROBABILITY; SAMPLE SIZE; STATISTICAL DISTRIBUTION; STATISTICAL MODEL;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BAYES THEOREM; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; DEOXYCYTIDINE; HEAD AND NECK NEOPLASMS; HUMANS; LEIOMYOSARCOMA; ORGANOPLATINUM COMPOUNDS; SAMPLE SIZE; TAXOIDS;

EID: 33746165107     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2450     Document Type: Article

References (19)

1. Mayo MS, Gajewski BJ. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors. Controlled Clinical Trials 2004; 25:157-167.
2. Tan SB, Machin D. Bayesian two-stage designs for phase II clinical trials. Statistics in Medicine 2002; 21: 1991-2012.
3. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10(1):1-10.
4. Thall PF, Estey EH. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation. Statistics in Medicine 1993; 12:1197-1211.
5. Berry DA. A case for Bayesianism in clinical trials. Statistics in Medicine 1993; 12:1377-1393.
6. Thall PF, Simon R. Practical guidelines for phase IIB clinical trials. Biometrics 1994; 50:337-349.
7. Lecoutre B, Derzko G, Grouin JM. Bayesian predictive approach for inference and proportions. Statistics in Medicine 1995; 14:1057-1063.
8. Abrams K, Ashby D, Errington D. Simple Bayesian analysis in clinical trials: a tutorial. Controlled Clinical Trials 1994; 15:349-359.
9. Brunier HC, Whitehead J. Sample sizes for phase II clinical trials derived from Bayesian decision theory. Statistics in Medicine 1994; 13:2493-2502.
10. Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Statistics in Medicine 1995; 14:357-379.
11. Etzioni R, Kadane JB. Optimal experimental design for another's analysis. Journal of the American Statistical Association 1993; 88:1404-1411.
12. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. Chapman and Hall: New York, 2000.
13. Jacobs C, Lyman G, Velez-Garcia E et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology, 1992; 10:257-263.
14. Liverpool Head and Neck Oncology Group. A phase III Bayesian trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. British Journal of Cancer 1990; 61:311 315.
15. Vogl SE, Schoenfeld DA, Kaplan BH et al. A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin and cisplatin in head and neck cancer. Cancer 1985; 56:432-442.
16. Thall PF, Sung HG. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Statistics in Medicine 1998; 17(14):1563-1580.
17. Casella G, Berger RL. Statistical Inference. Duxbury Press: Belmont, CA, 1990.
18. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unrectable leiomyosarcoma: results of a phase II trial. Journal of Clinical Oncology 2002; 20(12):2824-2831.
19. Garthwaite PH, Kadane JB, O'Hagan A. Statistical methods for eliciting probability distributions. Journal of the American Statistical Association 2005; 100(470):680-701.